Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Immunotherapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT03671265
What this trial is testing

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

Who this might be right for
Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital 20
Testing effectiveness (Phase 2)Study completedNCT04271384
What this trial is testing

Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer Stage I
Hospital Israelita Albert Einstein 25
Testing effectiveness (Phase 2)UnknownNCT05151549
What this trial is testing

Carilizumab Combined With Concurrent Chemoradiotherapy

Who this might be right for
Cervical Cancer
Hunan Cancer Hospital 46
Early research (Phase 1)UnknownNCT05928962
What this trial is testing

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Who this might be right for
Malignant Melanomas
Fujian Cancer Hospital 10
Testing effectiveness (Phase 2)Looking for participantsNCT06041503
What this trial is testing

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

Who this might be right for
Adenocarcinoma of the BladderSquamous Cell Carcinoma of the BladderTesticular Germ Cell Tumors
National Cancer Institute (NCI) 68
Testing effectiveness (Phase 2)UnknownNCT04777162
What this trial is testing

Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer

Who this might be right for
Gastric CancerColo-rectal Cancer
Peking University 40
Testing effectiveness (Phase 2)Study completedNCT02039674
What this trial is testing

Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)

Who this might be right for
Non-small Cell Lung Carcinoma
Merck Sharp & Dohme LLC 267
Early research (Phase 1)Looking for participantsNCT07231458
What this trial is testing

Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

Who this might be right for
Advanced Solid Tumors
Abalos Therapeutics GmbH 27
Testing effectiveness (Phase 2)Ended earlyNCT03514017
What this trial is testing

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute 5
Not applicableLooking for participantsNCT06485271
What this trial is testing

A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

Who this might be right for
Gastric CancerRWSPD-1 Immunotherapy
Changzhi People's Hospital Affiliated to Changzhi Medical College 504
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07138989
What this trial is testing

EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University 10
Early research (Phase 1)Looking for participantsNCT06411691
What this trial is testing

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

Who this might be right for
Colorectal CancerPancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 54
Testing effectiveness (Phase 2)Active Not RecruitingNCT03813394
What this trial is testing

Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC

Who this might be right for
Locally Recurrent CancerMetastatic Nasopharyngeal Cancer
National University Hospital, Singapore 48
Not applicableLooking for participantsNCT06635954
What this trial is testing

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

Who this might be right for
CancerImmunotherapyPD-1+2 more
Oxford Biodynamics Inc. 2,000
Not applicableStudy completedNCT04253080
What this trial is testing

Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors

Who this might be right for
Cutaneous Melanoma
Assistance Publique - Hôpitaux de Paris 127
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07515469
What this trial is testing

A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk

Who this might be right for
HCC - Hepatocellular CarcinomaIparomlimab and Tuvonralimab InjectionNeoadjuvant Immunotherapy
Tianjin Medical University Cancer Institute and Hospital 30
Not applicableLooking for participantsNCT07483112
What this trial is testing

Fiber-Boost Randomized Controlled Trial

Who this might be right for
Non-Small Cell Carcinoma of Lung
Cantonal Hospital of St. Gallen 42
Early research (Phase 1)UnknownNCT03966209
What this trial is testing

Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant

Who this might be right for
Hepatocellular CarcinomaLiver Transplantation
Shanghai Zhongshan Hospital 20
Testing effectiveness (Phase 2)Study completedNCT04225390
What this trial is testing

Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy

Who this might be right for
Immunotherapy
University of Erlangen-Nürnberg Medical School 38
Not applicableLooking for participantsNCT07086300
What this trial is testing

Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC

Who this might be right for
Elderly Patients (>65 Years)Non-Small Cell Lung CancerPD-1 Inhibitors+1 more
Kong Fanming 120
Next Page